Biofortis
Biofortis is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Enrollment occurred globally from 2 July 2024 to 3 June 2025, with 168 participants enrolled across 11 countries, including 94 in EU/EEA countries.
- Three adolescents were enrolled, all outside the EU/EEA.
These findings describe the trial, not the service provider’s performance or responsibility.
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
Sponsor Maat Pharma
- Start (EU)
- Latest update
- Estimated end
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
Sponsor MaaT PHARMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 67 subjects versus 75 planned, with 66 subjects treated and included in the efficacy and safety analysis sets.
- Subjects were enrolled in France, Spain, Belgium, Italy, Germany, and Austria.
- The exclusion criterion for liver Stage 4 and/or skin Stage 4 acute graft-versus-host disease was removed in protocol Version 5.0 dated 10 August 2022.
These findings describe the trial, not the service provider’s performance or responsibility.
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study randomized 308 participants at 70 centers in Australia, Belgium, Denmark, France, Germany, Italy, Japan, Norway, Puerto Rico, Spain, Sweden, the United Kingdom, and the United States.
- Enrollment was concentrated in France (102 participants), the United Kingdom (56), Italy (48), and Spain (31), while each other reporting country enrolled 2-19 participants.
- A December 2021 global protocol amendment removed interim analyses and clarified eligibility criteria.
- A May 2022 global protocol amendment updated eligibility criteria for Japanese participants.
- A February 2025 global protocol amendment updated the frequency of imaging during the disease follow-up phase.
These findings describe the trial, not the service provider’s performance or responsibility.
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
Sponsor MaaT PHARMA
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Efficacy, safety, and dose-response of a Live Biotherapeutic Product (BGY-1601-VT, vaginal tablet) as a first-line monotherapy in women with acute vaginal infection: a randomized, double-blind, placebo-controlled study
Sponsor Nexbiome Therapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Biofortis?
The 2026-10-09 snapshot links Biofortis to 12 distinct CTIS trials. Recorded services include Laboratory services, Sample tracking, Sample Tracking and Management, Clinical monitoring, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Biofortis?
The most frequently recorded therapeutic areas are Neurology, Gastroenterology, Transplantation, Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Biofortis conducted?
The linked trials record locations in 16 countries, including France, Spain, Italy, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Biofortis delivered services.
What can this page tell me about Biofortis's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Biofortis. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Biofortis